RT Journal Article
T1 Skin Barrier Function in Psoriasis and Atopic Dermatitis: Transepidermal Water Loss and Temperature as Useful Tools to Assess Disease Severity.
A1 Montero-Vilchez, Trinidad
A1 Segura-Fernández-Nogueras, María-Victoria
A1 Pérez-Rodríguez, Isabel
A1 Soler-Gongora, Miguel
A1 Martinez-Lopez, Antonio
A1 Fernández-González, Ana
A1 Molina-Leyva, Alejandro
A1 Arias-Santiago, Salvador
K1 atopic dermatitis
K1 homeostasis
K1 psoriasis
K1 skin barrier
K1 transepidermal water loss
AB Multiple diagnostic tools are used to evaluate psoriasis and atopic dermatitis (AD) severity, but most of them are based on subjective components. Transepidermal water loss (TEWL) and temperature are skin barrier function parameters that can be objectively measured and could help clinicians to evaluate disease severity accurately. Thus, the aims of this study are: (1) to compare skin barrier function between healthy skin, psoriatic skin and AD skin; and (2) to assess if skin barrier function parameters could predict disease severity. A cross-sectional study was designed, and epidermal barrier function parameters were measured. The study included 314 participants: 157 healthy individuals, 92 psoriatic patients, and 65 atopic dermatitis patients. TEWL was significantly higher, while stratum corneum hydration (SCH) (8.71 vs. 38.43 vs. 44.39 Arbitrary Units (AU)) was lower at psoriatic plaques than at uninvolved psoriatic skin and healthy controls. Patients with both TEWL > 13.85 g·m-2h-1 and temperature > 30.85 °C presented a moderate/severe psoriasis (psoriasis area severity index (PASI) ≥ 7), with a specificity of 76.3%. TEWL (28.68 vs. 13.15 vs. 11.60 g·m-2 h-1) and temperature were significantly higher, while SCH (25.20 vs. 40.95 vs. 50.73 AU) was lower at AD eczematous lesions than uninvolved AD skin and healthy controls. Patients with a temperature > 31.75 °C presented a moderate/severe AD (SCORing Atopic Dermatitis (SCORAD) ≥ 37) with a sensitivity of 81.8%. In conclusion, temperature and TEWL values may help clinicians to determine disease severity and select patients who need intensive treatment.
SN 2077-0383
YR 2021
FD 2021-01-19
LK https://hdl.handle.net/10668/26443
UL https://hdl.handle.net/10668/26443
LA en
DS RISalud
RD Apr 12, 2025